Showing results (1931-1940 of 3,040) with videos related to

Sort By:
Pageof 304
ACS Omega|March 10, 2025
3D Nanowire Pt Catalysts with Enhanced Stability for the Oxygen Reduction ReactionJoshua S White, Wanli Liu, Samuel C Perry, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Activity-dependent lipid droplet biogenesis and turnover regulate synaptic integrityEleni Katafygiotou, Ada Squires, Anne Liang, et al.
International Journal of Nursing Studies Advances|July 26, 2026
Changes in nurses' quality of work life prior to and during COVID: A repeated cross-sectional analysisIsaiah Hipel, Janice Keefe, Amber Duynisveld, et al.
Epilepsia|April 29, 1999
Criterion-based validity of an intracarotid amobarbital recognition-memory protocolJ McGlone, S E Black, J Evans, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjectsRobert DiCenzo, Alan Forrest, Kathleen E Squires, et al.
The Journal of Bone and Joint Surgery. British Volume|July 20, 2011
Total hip replacement and hemiarthroplasty in mobile, independent patients with a displaced intracapsular fracture of the femoral neck: a seven- to ten-year follow-up report of a prospective randomised controlled trialP P Avery, R P Baker, M J Walton, et al.
Computers, Informatics, Nursing : CIN|October 11, 2011
Organizational factors associated with decreased mortality among Veterans Affairs patients with an ICU stayAnne E Sales, Gwendolyn G Lapham, Janet Squires, et al.
IEEE Nuclear Science Symposium Conference Record. Nuclear Science Symposium|May 5, 2009
Human-observer LROC study of lesion detection in Ga-67 SPECT images reconstructed using MAP with anatomical priorsAndre Lehovich, Philippe P Bruyant, Howard C Gifford, et al.
Cryobiology|August 4, 2009
Osmotic tolerance limits and membrane permeability characteristics of stallion spermatozoa treated with cholesterolAmanda I Glazar, Steven F Mullen, Jun Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2005
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignanciesRobert J Kreitman, David R Squires, Maryalice Stetler-Stevenson, et al.
Pageof 304